Roche’s Genentech has broken ground for a new $450-million biologics manufacturing facility at its Oceanside, California campus. With the new facility, the company plans to add approximately 150 jobs to its campus. 

When operational in early 2025, the facility will be the company’s first location for commercial production of biologics for smaller patient populations, including products to treat rare diseases and personalized medicines. The facility will be built with a modular design to allow for simultaneous production of multiple medicines and with a sustainable design for improved environmental performance.   

Source: Genentech